High dose famotidine in ranitidine resistant severe oesophagitis: a pilot study

N Z Med J. 1990 Apr 11;103(887):150-2.

Abstract

Fifty-three asymptomatic patients who, in spite of continuous treatment with ranitidine 300 mg bid for six months, had active severe oesophagitis, Savary and Miller grade III-IV or Barretts ulceration at endoscopy were treated with high dose famotidine. In the severe oesophagitis group famotidine 40 mg bid, 13/29 (44%) healed at eight weeks and 17/29 (58%) at sixteen weeks. In the Barrett's ulcer group famotidine 40 mg tid, 10/24 (41%) healed at eight weeks and 18/24 (75%) at sixteen weeks. Famotidine in high doses was well tolerated in this age group (mean 66.75 years), with 5/53 (9%) minor adverse events recorded. Famotidine in high dose is effective in the treatment of ranitidine resistant severe oesophagitis or Barrett's ulceration.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Barrett Esophagus / drug therapy*
  • Drug Administration Schedule
  • Esophagitis, Peptic / drug therapy*
  • Famotidine / administration & dosage*
  • Famotidine / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Ranitidine / therapeutic use

Substances

  • Famotidine
  • Ranitidine